Swiss Pharma Company Announces $50 Billion US Investment, 12,000 New Jobs

The announcement follows a recent announcement by another Swiss pharma entity of a $23 billion investment in the United States.

The logo of pharmaceutical giant Roche in Basel, Switzerland. Fabrice Coffrini/AFP/Getty Images

Switzerland-based pharmaceutical company Roche will invest $50 billion in the United States over a five-year period, setting up new facilities and expanding existing ones, the company said in an April 22 statement.

The investments “are expected to create more than 12,000 new jobs, including nearly 6,500 construction jobs, as well as 1,000 jobs at new and expanded facilities,” according to the statement.

As part of the investments, a gene therapy-manufacturing facility will be opened in Pennsylvania, along with a new manufacturing facility in Indiana for continuous glucose monitoring, and a 900,000-square-foot manufacturing facility to support the company’s weight-loss medicine portfolio.

A new research and development (R&D) center in Massachusetts is also being planned, which aims to conduct “cutting-edge artificial intelligence (AI) research” and serve as a “hub for our new cardiovascular, renal, and metabolism research and development efforts,” Roche said.

The company’s manufacturing and distribution capabilities in California, Indiana, Kentucky, New Jersey, and Oregon will be expanded and upgraded.

Its existing pharmaceutical and diagnostics R&D centers in Arizona, California, and Indiana will also see “significant” expansion and upgrades.

Roche is not the only Swiss pharmaceutical company to announce expanded U.S. operations in response to the tariff announcements.

On April 10, Swiss pharma company Novartis revealed plans to invest $23 billion over the next five years in the United States in a bid to boost manufacturing and research operations.

Novartis said the investment will allow the company to manufacture 100 percent of its key drugs within the country end-to-end.

The Roche and Novartis announcements come after President Donald Trump unveiled a 10 percent minimum baseline tariff and reciprocal tariffs on dozens of nations on April 2. The reciprocal tariffs have been paused for a period of 90 days.

Tariffs on pharmaceutical products are also on the cards.

Swiss goods are facing 31 percent U.S. tariffs. A Swiss delegation is scheduled to hold bilateral talks with Washington that will continue until April 25.

According to Roche, after the expanded and new manufacturing capacity comes online, the company expects to export more medicines from the United States than it imports.

“Today’s announced investments underscore our long-standing commitment to research, development, and manufacturing in the U.S.,” Thomas Schinecker, Roche Group CEO, stated.

“Our investments of US$50 billion over the next five years will lay the foundation for our next era of innovation and growth, benefiting patients in the U.S. and around the world.”

The company already has 13 manufacturing sites in the United States and 15 R&D centers, which combined employ over 25,000 workers.

Pharma Tariffs

During an April 8 speech at the National Republican Congressional Committee, Trump said pharma tariffs will soon be implemented.

“And once we do that, they’re gonna come rushing back into our country because we are the big market,” he said.

“The advantage we have over everybody is that we are the big market. So, we’re gonna be announcing, very shortly, a major tariff on pharmaceuticals. And when they hear that, they will leave China, they will leave other places, because most of their products are sold here.”

Last week, Federal Register notices revealed that the Commerce Department launched an investigation into the effects of importing pharmaceutical products and semiconductors on national security.

The investigations were initiated under Section 232 of the Trade Expansion Act, which empowers the president to implement tariffs on imported items deemed to be a national security threat.

A Feb. 19 post by ING bank said that European companies would be the most affected by pharma import tariffs.

The bank estimated the United States to have consumed about $560 billion worth of pharmaceutical products in 2024, out of which roughly $200 billion (36 percent) worth of products were imported.

“In recent years, Ireland has been the main import partner of the U.S., followed by Germany and Switzerland, and these are the countries that are going to be hit particularly hard should the threat become a reality,” ING said.